Enterprise Innovation brings internal and external collaboration opportunities to our faculty and trainees. These programs provide extra funding and opportunities to work with industry to advance faculty/trainees' translational research projects.
1. Mission BioCapital 2024 Platinum Program
- Eligibility: Mission BioCapital is an early-stage biotech fund with a strong preference for novel therapeutics that opportunistically invests in adjacencies including medtech and diagnostics. They are disease- and modality-agnostic. They are looking for a team with at least 1 full-time dedicated person who will be advancing the science in their affiliated labs and responsible for developing the fundraising strategy and business model. In some situations, there are several people already a part of the company who divide these responsibilities among themselves. Mission BioCapital is happy to discuss further as well.
- Platinum Program will award up to six winning startup-ups with:
- A guaranteed lab bench in one of Mission BioCapital’s affiliated incubators located in 13 cities in the U.S. and Europe
- Up to $500,000 of seed capital per awardee
- Drug discovery services from Alloy Therapeutics to enable companies with a de-risked pathway to lead candidate
- Strategic scientific and business development mentorship from experts across Mission BioCapital’s corporate network, including sponsors Mission BioCapital, Lilly, OVI, and Alloy Therapeutics
- Final Deadline for Application Submission: July 15, 2024
Applicants that will move on as a finalist will receive information about the process in August 2024. All final decisions will be communicated by the end of September 2024. Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
2. Alzheimer’s Drug Discovery Foundation – Accelerating Drug Discovery For Frontotemporal Degeneration
- Eligibility: Academics or biotechs looking to accelerate therapeutic development progress for small molecule, biologic, genetic therapy agents to treat FTD and related neurodegenerative disease
- RFP supports lead optimization, med chem, in vivo testing of compounds for PK, dose-range finding, tolerability, in vivo efficacy
- Funding Duration: 1 year w/ potential for follow-on
- Funding Amount: $300k - $350k based on stage of development
- LOI Deadline: May 13, 2024
- Invited Full Proposal Deadline: July 22, 2024
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
3. Alzheimer’s Drug Discovery Foundation – Drug Development RFP
- Eligibility: Investigators seeking to support IND enabling studies or early phase clinical trials for pharmacological interventions or devices for AD and other dementias (disease modifying or symptomatic therapies considered)
- RFP supports early clinical trials, biomarker based POC studies, non-GLP and GLP pharmacology/tox, formulation, GMP manufacturing of API
- Funding Duration: Multi-year
- Funding Amount: Up to $5M based on scope and stage of research
- LOI Deadline: May 13, 2024
- Invited Full Proposal: July 22, 2024
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
4. Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker Program
- Eligibility: Investigators seeking to further develop and validate established clinical biomarkers in Alzheimer’s and related dementias. Priority on biomarkers with defined context of use, clinical relevance, and commercial path. Special focus on:
- Novel PET ligands for clinical trials
- Novel CSF biomarkers
- Validating innovative MRI approaches in larger cohorts
- Developing novel measures of functional activity such as EEG
- Funding Duration: 1 year w/ potential to follow on
- Funding Amount: Up to $600k based on stage and scope research
- LOI Deadline: May 13, 2024
- Invited Full Proposal: July 22, 2024
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
5. FuzeHub – 2024 Manufacturing Grants
- Eligibility: Academic researchers/entrepreneurs who are partnering with at least one NY state small – medium sized life sciences manufacturer to support:
- New Technology Development
- Prototype Development
- Design and POC for Manufacturing
- Manufacturing Scale Up
- Equipment Purchases
- Funding Duration: 1 year
- Funding Amount: $65k
- Application Deadline: May 14, 2024
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
6. Nathan Shock Centers of Excellence in Basic Biology of Aging (P30, no clinical trial)
- Application Deadline: May 15, 2024
- Award Details: Up to $1.1M per year, 5 year maximum
- Funding opportunity for applicants with a research focus in: hallmarks of aging, biomarkers of aging, computational modeling aging, pharmacological gerotherapeutics development, translational models for drug screening
- Informational webinar April 9 for NSC application, register here
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
7. BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18, no clinical trial)
- Application Deadline: May 29, 2024
- Award Details: Up to $750k per year, 3 year maximum
- Funding opportunity for research which aims to translate novel recording and modulation technologies that could be used to treat and/or diagnose CNS diseases
- Eligible projects include proof of concept stage through FIH clinical readiness. Devices may incorporate any signal modality (electrical, optical, magnetic, acoustic)
- Plan for Enhancing Diverse Perspectives will be required for application
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
8. BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3, clinical trial optional)
- Application Deadline: May 29, 2024
- Award Details: Up to $500k per year in UG3 phase, up to $1.5M per year in UH3 phase
- Funding opportunity for neuroscience projects with transdisciplinary, collaborative researchers in fields of computational biology, physics, engineering, and data sciences; encourages participation of early-mid career investigators from diverse, under-represented backgrounds
- Opportunity aims to encourage applicants to pursue milestone-driven translational and clinical projects for recording and/or stimulating devices to treat CNS disorders
- Award will support regulatory activities needed for IND enabling work and subsequently FIH or early stage clinical study
Please contact James Bellush at james.bellush@cornell.edu if you have any questions.
9. Sanofi iAwards North America 2024 – 2025
Objective: Translational research award seeks to convert promising early stage, disease relevant projects into sponsored research programs and subsequently licensing / start-up opportunities within the Sanofi early stage pipeline
Eligibility Guidelines:
- Pre-proposals must be non-confidential
- Must not include 3rd party collaborators (academic partners permitted)
- Must outline research milestones and work-plan achievable in 12 mos
- Learn more about the therapeutic areas of interest and view detailed timeline for submission
here. A pre-proposal template is available here.
*CTL office must validate the application prior to submission
- Please provide CTL contact email in “General Information”:
- James Bellush, Manager, Scientific Scouting
- Email: james.bellush@cornell.edu
Award and Application Information:
- $150,000 for 12 months (direct + indirect costs included)
- Additional R&D support and guidance included from Sanofi
- After CTL review is complete, pre-proposal submitted through this link
- Pre-proposals must be submitted to Sanofi by June 3, 2024
- Submission of completed Full Proposals to Sanofi by Institutions by September 2, 2024